A virtual roundtable discussion with Drs Joseph A Sparano and
Eric P Winer reviewing recent innovations in the treatment of early
breast cancer.
Comparison of patient risk classifications by genomic assays
for patients with early-stage breast cancer (00:00)
Prognostic gene expression assays in breast cancer: Are 2
better than 1? (06:13)
Implications of gene expression assay results for therapeutic
decision-making (07:51)
Design and results of the Phase III TAILORx trial evaluating
chemoendocrine therapy versus endocrine therapy alone for patients
with ER-positive, HER2-negative, node-negative breast cancer and an
intermediate 21-gene assay Recurrence Score® (RS)
(11:19)
Clinical implications of the TAILORx trial for treatment
decision-making for patients older than 50 with ER-positive early
breast cancer (EBC) (16:24)
Prediction of chemotherapy benefit by RS for patients 50 years
or younger with ER-positive EBC (17:51)
Benefit with the addition of ovarian suppression to endocrine
therapy for premenopausal women with ER-positive breast cancer at
high risk for recurrence (22:18)
Case (Dr Winer): A woman in her early 60s with
Grade III ER-positive, HER2-negative, node-negative breast cancer
has a 2.1-cm tumor and a RS of 25 (24:30)
Risk of recurrence and benefit from chemotherapy for
postmenopausal women with EBC (27:57)
Significance of clinical risk category in prognosis and
prediction of chemotherapy benefit by age and RS in the
TAILORx trial (33:06)
Perspective on the use of Ki-67 as a biomarker in breast cancer
(36:11)
Clinical and genomic risk to guide the use of adjuvant therapy
for breast cancer (37:55)
Implications of the TAILORx trial results for the use of
neoadjuvant endocrine therapy (40:10)
Case (Dr Sparano): A woman in her early 60s
with Stage IIA ER-positive, HER2-negative lobular breast cancer, a
RS of 19 and a high ESR1 RNA score receives adjuvant
docetaxel/cyclophosphamide followed by anastrozole (45:45)
Tolerability and quality of life during treatment with
chemotherapy (50:09)
Change in perspective for oncology professionals diagnosed with
cancer (50:50)
Impact of the RS-pathology-clinical (RSPC) score on the
assessment of recurrence risk for patients with breast cancer
(55:01)
Case (Dr Winer): A woman in her late 30s with
Grade II ER-positive, node-negative breast cancer and a RS of 20
receives treatment with ovarian suppression and tamoxifen
(58:12)
Case (Dr Winer): A woman in her late 50s with
ER-positive lobular breast cancer, a 5.2-cm tumor, 1 palpable lymph
node and a RS of 8 receives neoadjuvant endocrine therapy and a
CDK4/6 inhibitor on a clinical trial (1:03:43)
Case (Dr Sparano): A woman in her early 60s
with Stage IIA ER-positive, node-positive right breast cancer (RS
7) and Stage IA left breast cancer experiences a good response to
adjuvant anastrozole alone (1:07:21)
Prognostic effect of the 21-gene assay RS for patients with
high-risk ER-positive EBC and 1 to 3 positive nodes (1:10:19)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.